Spin-out of Monument Therapeutics

Insights Back to resource centre 1 July 2021 Spin-out of Monument Therapeutics Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to central nervous system (“CNS”) disorders. Cambridge Cognition has been incubating Monument Therapeutics since 2018, with early-stage research supported by two Innovate UK grants. Monument Therapeutics applies

Spin-out of Monument Therapeutics Read More »

Spin-out of Monument Therapeutics

News Back to resource centre 1 July 2021 Spin-out of Monument Therapeutics Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to central nervous system (“CNS”) disorders.Cambridge Cognition has been incubating Monument Therapeutics since 2018, with early-stage research supported by two Innovate UK grants. Monument Therapeutics applies a novel drug development

Spin-out of Monument Therapeutics Read More »

New £2.2 million contract for at-home cognitive testing in a virtual clinical trial

News Back to resource centre 28 June 2021 New £2.2 million contract for at-home cognitive testing in a virtual clinical trial Cambridge Cognition has been selected as the cognitive assessment partner for a large at-home study. The contract is valued at £2.2 million with revenue expected to be recognised by the Company over three years beginning in H2 2021.This is

New £2.2 million contract for at-home cognitive testing in a virtual clinical trial Read More »

Validation of a Smartphone-based Digit Symbol Substitution Task in Participants With Major Depression

Insights Back to resource centre 8 April 2021 Validation of a Smartphone-based Digit Symbol Substitution Task in Participants With Major Depression At the virtual ISCTM – Annual Scientific Meeting, Luke Allen presented data supporting the validity of Smartphone-based DSST for assessments in patient populations such as MDD. Read on for the key findings and the full poster: Validation and Comparability

Validation of a Smartphone-based Digit Symbol Substitution Task in Participants With Major Depression Read More »

CANTAB and CENTRE-TBI – 10 years working together

Insights Back to resource centre 1 April 2021 CANTAB and CENTRE-TBI – 10 years working together CENTRE-TBI recently concluded their 10 year study into the relationship between cognition and function in daily life after traumatic brain injury. We caught up with Prof Lindsay Wilson to hear the key findings from this worldwide study. Can you tell us more about your

CANTAB and CENTRE-TBI – 10 years working together Read More »

What is the association between anabolic androgenic steroid dependence and executive dysfunction?

Insights Back to resource centre 2 February 2021 What is the association between anabolic androgenic steroid dependence and executive dysfunction? We recently spoke with Dr Lisa Evju Hauger to discuss the impact CANTAB had on her research into exploring executive function in relation to long-term anabolic androgenic steroids (AAS) use and dependence. The Anabolic Androgenic Research Group are a multidisciplinary

What is the association between anabolic androgenic steroid dependence and executive dysfunction? Read More »

Shows the nutrients in the brain

Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, carotenoids and vitamin E on the cognitive health and function of patients with MCI.

Insights Back to resource centre 16 November 2020 Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, carotenoids and vitamin E on the cognitive health and function of patients with MCI. Dr Rebecca Power, Postdoctoral Researcher at the Nutrition Research Centre Ireland, shared the role that CANTAB played in her latest publication: Targeted Nutritional

Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, carotenoids and vitamin E on the cognitive health and function of patients with MCI. Read More »

Virtual clinical trials: What have we learned in the era of Covid-19?

Webinars Back to resource centre 11 January 2023 Virtual clinical trials: What have we learned in the era of Covid-19? Industry experts working at the forefront of drug development and digital health share lessons learned delivering virtual trials during the Covid-19 pandemic. Catch up on a thought-leading discussion on how to mature the accelerated adoption of digital trials during lockdown

Virtual clinical trials: What have we learned in the era of Covid-19? Read More »

Remote Cognitive Testing and Lessons Learned During Lockdown

Webinars Back to resource centre 11 January 2023 Remote Cognitive Testing and Lessons Learned During Lockdown Traditionally, scientists assess cognition with thorough, but infrequent, testing sessions in a tightly controlled laboratory environment. In efforts to curb Covid-19 transmission rates, most researchers have postponed this form of face-to-face assessment. Between the longevity of this pandemic-driven lockdown, and the significant risk of

Remote Cognitive Testing and Lessons Learned During Lockdown Read More »

Wearable Technology for High-Frequency Cognitive and Mood Assessments in Depression

Webinars Back to resource centre 11 January 2023 Wearable Technology for High-Frequency Cognitive and Mood Assessments in Depression Despite the obvious advantages of conducting thorough assessments in highly controlled laboratory environments, the associated resource burden means that such lengthy assessments are out of the question for daily testing. The widespread adoption of smartphones and wearables makes monitoring symptoms in real

Wearable Technology for High-Frequency Cognitive and Mood Assessments in Depression Read More »

Scroll to Top